rFSH (Follitropin alfa)

Follitropin alfa is manufactured FSH, the fertility hormone in Gonal-F. Men discuss it when sperm production remains poor despite hCG, including during or after testosterone replacement therapy (TRT). Reports include improved sperm counts, delayed partial responses and continuing uncertainty; feeling better on testosterone does not show that fertility has returned.

FSH supports the sperm-producing cells. The community's two-signal explanation separates FSH's support of sperm production from hCG's support of testosterone inside the testes. A normal blood testosterone result alone does not answer the sperm question.

Gonal-F is follitropin alfa. It is recombinant FSH, delivered under the skin by pen or vial. GONAL-f: EMA product information (Official context · Accessed 2026-09-30)

HMG and follitropin beta are different products. HMG, including Menopur, supplies both FSH and LH activity. Follistim and Puregon contain follitropin beta. These nearby names do not make the products identical, and combination reports cannot isolate alfa's contribution.

Source context — GONAL-f: EMA product information: Formal product-specific context; repeated formulations are not independent studies. Does not verify any user's product identity or TRT-on-board effectiveness.

Sperm production can improve without an obvious sensation. A contributor with low FSH but normal LH and testosterone reported a rise from almost no sperm to 3.7 million total after four months of FSH-only treatment. That isolated deficiency differs from infertility after TRT. Gonal-F solo? (Personal report · Accessed 2026-09-30)

Movement and count can change at different times. The 2026 TRT journey reported unchanged concentration at six weeks but improved forward movement, then higher concentration by twelve weeks. The author used Gonal-F and Foligraf with hCG and testosterone, mainly tracking through a home test; no conception outcome was reported. rFSH, HCG and TRT - My Fertility Journey and Experience. (Personal report · Accessed 2026-09-30)

An eight-month title was not eight months of FSH. The delayed-response poster began hCG in January 2025 and FSH in April. Their August result, posted later, found rare sperm below 1 million/mL with movement too low to assess. Two repeated updates describe that same result. No sperm after 8 months on HCG + FSH — need advice (Personal report · Accessed 2026-09-30)

Hope and a limited response can coexist. The delayed-response poster eventually found rare sperm. Another commenter reported 7.5 million total after three months while staying on low-dose TRT. Those are different people; sperm concentration per mL and total count are different measures, and neither establishes pregnancy. No sperm after 8 months on HCG + FSH — need advice (Personal report · Accessed 2026-09-30)

Fuller testes are not a fertility test. The preserved discussion describes less shrinkage with hCG-containing combinations. Appearance, libido and testosterone levels do not establish sperm count or quality. Gonal-F solo? (Personal report · Accessed 2026-09-30)

FSH supports the sperm-producing cells. The community's two-signal explanation separates FSH's support of sperm production from hCG's support of testosterone inside the testes. A normal blood testosterone result alone does not answer the sperm question.

Source context — Gonal-F solo?: Different contributors and diagnoses; not verified clinical records. Some more-reply branches were not expanded. No pregnancy confirmation inspected.

Source context — rFSH, HCG and TRT - My Fertility Journey and Experience.: Gonal-F and Foligraf named together; rFSH injection route not explicit. Home testing dominates tracking, accompanying hCG/testosterone and supplements changed. Reported zero rFSH side effects is the same author's claim. Baseline test followed treatment start; no pregnancy endpoint. Sourcing discussion intentionally excluded.

Source context — No sperm after 8 months on HCG + FSH — need advice: Eight months refers to overall recovery timeline, not eight months of FSH. Repeated rare-sperm updates are one result; No_City_1642's two comments are one user. Routes are not explicit; no confirmed conception outcome.

75 IU per injection, three times weekly. IU means international units, not micrograms. One man coming off long-term TRT reported Gonal-F at this frequency alongside hCG. Another commenter used 75 IU daily while retaining 50–75 mg testosterone weekly. Those frequencies represent different exposure, not interchangeable versions of one dose. No sperm after 8 months on HCG + FSH — need advice (Personal report · Accessed 2026-09-30)

75 IU every other day, later 125 IU every other day. The 2026 journey increased after six weeks and named both Gonal-F 900 and Foligraf 1200 kits. These are per-injection amounts; kit totals are not single doses. The post does not explicitly document the rFSH injection route. rFSH, HCG and TRT - My Fertility Journey and Experience. (Personal report · Accessed 2026-09-30)

75–150 IU two or three times weekly also circulates. This is the older TRT-fertility discussion band, not a verified optimum. IVF reports describe separate ovarian-stimulation amounts, including 150 IU Gonal-F with 75 IU Menopur; the components and indication must remain distinct. Gonal -f (Personal report · Accessed 2026-09-30)

Source context — No sperm after 8 months on HCG + FSH — need advice: Eight months refers to overall recovery timeline, not eight months of FSH. Repeated rare-sperm updates are one result; No_City_1642's two comments are one user. Routes are not explicit; no confirmed conception outcome.

Source context — rFSH, HCG and TRT - My Fertility Journey and Experience.: Gonal-F and Foligraf named together; rFSH injection route not explicit. Home testing dominates tracking, accompanying hCG/testosterone and supplements changed. Reported zero rFSH side effects is the same author's claim. Baseline test followed treatment start; no pregnancy endpoint. Sourcing discussion intentionally excluded.

Source context — Gonal -f: Ovarian treatment, not male/TRT evidence. Co-medications and underlying fertility features differ. Posted daily context is stimulation discussion, but not every reply specifies frequency; no inferred male dose or response.

Six weeks without a count increase; later improvement. The 2026 journey's first change was sperm movement, with concentration rising later. A different FSH-only contributor reported a count change after four months. These are testing histories, not deadlines or immediate felt effects. rFSH, HCG and TRT - My Fertility Journey and Experience. (Personal report · Accessed 2026-09-30) · Gonal-F solo? (Personal report · Accessed 2026-09-30)

Movement and count can change at different times. The 2026 TRT journey reported unchanged concentration at six weeks but improved forward movement, then higher concentration by twelve weeks. The author used Gonal-F and Foligraf with hCG and testosterone, mainly tracking through a home test; no conception outcome was reported. rFSH, HCG and TRT - My Fertility Journey and Experience. (Personal report · Accessed 2026-09-30)

No dependable one-injection benefit window. Older discussion separates injection frequency from semen-testing calendars. Sperm production is followed across months rather than hours of energy or libido; it gives no dependable lasting-benefit window after the last injection.

Stopping is a separate uncertainty. Older discussion warns that sperm may fall again if TRT continues while FSH and hCG stop. It supplies no dependable relapse interval or lasting fertility assurance.

Measured half-lives. EMA: under-skin 24–59 hours; intravenous early phase about 2 hours, late decline 14–17 hours. US under-skin: healthy women with hormones suppressed, 150 IU single 24±11 hours, repeated 24±8; healthy men, 225 IU single 41±14, repeated 32±4. US single-dose women: 66±39% reached blood. These estimates do not measure fertility duration. GONAL-F multidose: US prescribing information (Official context · Accessed 2026-09-30) · GONAL-f: EMA product information (Official context · Accessed 2026-09-30)

Source context — rFSH, HCG and TRT - My Fertility Journey and Experience.: Gonal-F and Foligraf named together; rFSH injection route not explicit. Home testing dominates tracking, accompanying hCG/testosterone and supplements changed. Reported zero rFSH side effects is the same author's claim. Baseline test followed treatment start; no pregnancy endpoint. Sourcing discussion intentionally excluded.

Source context — Gonal-F solo?: Different contributors and diagnoses; not verified clinical records. Some more-reply branches were not expanded. No pregnancy confirmation inspected.

Source context — GONAL-F multidose: US prescribing information: Initial direct open failed, but a subsequent find on the indexed exact page returned full body and follow-up open succeeded. Male trial participants also received hCG. PK table estimates do not measure fertility duration.

Source context — GONAL-f: EMA product information: Formal product-specific context; repeated formulations are not independent studies. Does not verify any user's product identity or TRT-on-board effectiveness.

Months of follow-up, not a short peptide cycle. Older discussion describes 3–12-month courses and conception windows, without an agreed break or repeat calendar. Its roughly 70-day sperm-development figure describes background biology, not a deadline that proves treatment succeeded or failed.

Staying on TRT and stopping it are different histories. The discussion divides between recovering fertility after stopping testosterone and trying to retain TRT's benefits while adding fertility drugs. Cost, time pressure and different underlying diagnoses prevent treating either path as a universal answer.

FSH supports the sperm-producing cells. The community's two-signal explanation separates FSH's support of sperm production from hCG's support of testosterone inside the testes. A normal blood testosterone result alone does not answer the sperm question.

75 IU per injection, three times weekly. IU means international units, not micrograms. One man coming off long-term TRT reported Gonal-F at this frequency alongside hCG. Another commenter used 75 IU daily while retaining 50–75 mg testosterone weekly. Those frequencies represent different exposure, not interchangeable versions of one dose. No sperm after 8 months on HCG + FSH — need advice (Personal report · Accessed 2026-09-30)

hCG combinations: hCG appears in the male label and many accounts. A separate low-FSH user with normal LH/testosterone reported improvement with FSH alone; different underlying diagnoses prevent treating missing hCG as the explanation for every nonresponse. [community]

Continued TRT: Some accounts retain testosterone while adding hCG and FSH. Improvement in a combined history does not establish each drug's contribution or guarantee preserved fertility. [community]

+ enclomiphene after coming off: Different restart path — not the same as rFSH. [community]

Combinations complicate both benefit and risk. hCG, testosterone and enclomiphene appear in older stack discussion. They are not interchangeable with FSH. These accounts do not establish safe interactions, estrogen-management rules or the safety of indefinite combination use.

Source context — No sperm after 8 months on HCG + FSH — need advice: Eight months refers to overall recovery timeline, not eight months of FSH. Repeated rare-sperm updates are one result; No_City_1642's two comments are one user. Routes are not explicit; no confirmed conception outcome.

No buzz does not mean no effects. Older accounts mention redness, itching and bruising. The 2026 author reported no specific rFSH side effects, but also acne and elevated estrogen during hCG changes. Their later improvement involved supplements and time, leaving attribution uncertain. rFSH, HCG and TRT - My Fertility Journey and Experience. (Personal report · Accessed 2026-09-30)

Breast changes occurred in combination trials. US trials reported breast enlargement in 4/63 men (6%), including surgery after nine months. hCG co-treatment prevents attributing it solely to FSH. GONAL-F multidose: US prescribing information (Official context · Accessed 2026-09-30)

The infertility diagnosis matters. The male label excludes primary testicular failure; normal blood testosterone cannot replace semen testing. GONAL-F multidose: US prescribing information (Official context · Accessed 2026-09-30)

Ovarian risks are a separate story. An IVF contributor reported mild ovarian hyperstimulation syndrome (OHSS) with 112.5 IU Gonal-F plus another drug. It means an excessive ovarian response, not a male testicular side effect; lower amounts do not eliminate it. Gonal -f (Personal report · Accessed 2026-09-30)

Pregnancy and serious reactions. Labels warn against pregnancy use and describe severe allergy, clotting complications and OHSS; fertility treatment does not establish pregnancy safety. GONAL-f: EMA product information (Official context · Accessed 2026-09-30) · GONAL-F RFF Redi-ject: US pen prescribing information (Official context · Accessed 2026-09-30)

Source context — rFSH, HCG and TRT - My Fertility Journey and Experience.: Gonal-F and Foligraf named together; rFSH injection route not explicit. Home testing dominates tracking, accompanying hCG/testosterone and supplements changed. Reported zero rFSH side effects is the same author's claim. Baseline test followed treatment start; no pregnancy endpoint. Sourcing discussion intentionally excluded.

Source context — GONAL-F multidose: US prescribing information: Initial direct open failed, but a subsequent find on the indexed exact page returned full body and follow-up open succeeded. Male trial participants also received hCG. PK table estimates do not measure fertility duration.

Source context — Gonal -f: Ovarian treatment, not male/TRT evidence. Co-medications and underlying fertility features differ. Posted daily context is stimulation discussion, but not every reply specifies frequency; no inferred male dose or response.

Source context — GONAL-f: EMA product information: Formal product-specific context; repeated formulations are not independent studies. Does not verify any user's product identity or TRT-on-board effectiveness.

Source context — GONAL-F RFF Redi-ject: US pen prescribing information: US pen label's female indications are not the US multidose male indication; different formulations/jurisdictions must not be silently combined.